In a phase 2 trial of 66 patients with early Parkinson's disease, 12 months of azathioprine did not improve off-state MDS-UPDRS gait-axial score versus placebo (mean change 0.54 vs 0.13; p=0.78); serious adverse events occurred in 24% vs 12%.
RCTn = 66
Greenland et al. Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial